Jon Ma discusses commentary by SemiAnalysis analyst Dylan Patel regarding model capabilities, market size, and the contractual definition of AGI between Microsoft and OpenAI.
“Dylan Patel said on Dorkesh, the TAM for GPC 5.4 is north of a hundred billion dollars, but there's adoption lag. That's considered AGI as far as the Microsoft OpenAI contract is concerned.”
quote is from the automated transcript, cleaned for reading:
filler sounds and stutters are removed, nothing is rephrased. names can be misheard
(the analysis reads context, assessments check outside sources). how →
More from Jon Ma
AssertionSupported
Jon Ma: AI enabled single individual to assemble biotech workflow
“Instead of requiring multiple experts, a motivated individual was able to assemble the workflow with AI acting as a kind of guide through the technical landscape.”
Jon MaMar 16, 2026▶ 17:59AI vs. Dog Cancer, Timothée Chalamet Under Fire, ‘Agents Over Bubbles' | Diet TBPN
AssertionContradicted
Carter: OpenAI IP Access Now Requires Expert Review, Not Just Profit
“Sam Carter says the reported one billion of profit is no longer the sole trigger for confidential IP research access. It reportedly includes an independent expert review.”
Jon MaMar 16, 2026▶ 19:59AI vs. Dog Cancer, Timothée Chalamet Under Fire, ‘Agents Over Bubbles' | Diet TBPN
Opinion
Ma: PC makers should fear Apple's $599 MacBook Neo
“The point about the MacBook Neo is that at five 99, a lot of PC makers should be sort of quaking in their boots because you're selling at that price point.”
Jon MaMar 16, 2026▶ 24:34AI vs. Dog Cancer, Timothée Chalamet Under Fire, ‘Agents Over Bubbles' | Diet TBPN
AssertionSupported
Ma: Nebius and Meta Agree to $27B AI Infrastructure Deal
“Nebius and Meta have agreed to a twenty seven billion dollar AI infrastructure pact, a deal. The talks are advanced to packed stage. A five-year deal, twenty-seven billion to supply AI infrastructure capacity to Meta.”
Jon MaMar 16, 2026▶ 27:53AI vs. Dog Cancer, Timothée Chalamet Under Fire, ‘Agents Over Bubbles' | Diet TBPN
AssertionSupported
Jon Ma: Lack of target validation is top reason for drug failure
“Since the hardest part of drug discovery, whether in humans or dogs, is target validation, the lack of which leads to a lack of efficacy. The number one reason for drug failure.”
Jon MaMar 16, 2026▶ 16:56AI vs. Dog Cancer, Timothée Chalamet Under Fire, ‘Agents Over Bubbles' | Diet TBPN
Made with StarZero
Turn any episode into a week of clips.
This entire site, over 500 episodes transcribed, diarized, checked and made playable,
runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the
moments worth sharing, cuts them, captions them, and reframes them for every feed.
We use essential cookies to make the site work. With your permission we
also use analytics cookies (Google Analytics and Mixpanel) to understand
usage and improve StarZero. See our Cookie Policy.
